Unlike everyday supplements stocked in every health store, CJC-1295 is distributed via a global research peptide market that Lédi residents navigate through international suppliers. The benefit of this online-only market is that serious vendors compete aggressively on their analytical documentation, giving researchers access to better quality signals than any physical store could provide. Vendors worth sourcing from proactively publish batch-matched Certificates of Analysis showing HPLC purity data, mass spec identity confirmation, endotoxin levels, and residual solvent results — all for the exact batch you are purchasing. The sections below cover what Lédi researchers need to know about sourcing, verifying, and handling CJC-1295 for research purposes.
Understanding CJC-1295 — Biology & Evidence
CJC-1295 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Lédi studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
Buying CJC-1295: Quality Markers to Look For
The first step for any Lédi researcher sourcing CJC-1295 is locating suppliers that experienced researchers actively recommend — organic rankings are no guide to actual CJC-1295 quality. Endotoxin testing in the COA is critical for any injectable research use — endotoxins from microbial contamination can trigger dangerous inflammatory cascades even at trace quantities. Red flags in CJC-1295 vendor evaluation: prices more than 30-40% below standard market rates, vague sourcing information, no community presence, and COAs that do not include endotoxin results. Price is an ineffective primary criterion for CJC-1295 quality — research-grade synthesis and testing has real costs that do not compress without quality compromise, so significantly below-market pricing signals compromises.
Order CJC-1295 — ships to Lédi
COA-verified · International tracking · Research grade
All use of CJC-1295 in Lédi or anywhere must be research use only — this compound is not approved for clinical human use, and all handling should follow research laboratory protocols. Reconstitute CJC-1295 with bacteriostatic water at the concentration suited to your research design; a standard 5mg reconstituted in 2mL produces 2.5mg/mL — providing 25mcg per unit measured on a 100-unit syringe. Quality CJC-1295 sourcing is not separable from research safety — bacterial endotoxin contamination, mislabeling, and degradation products are all safety issues that proper COA verification addresses. The research literature on CJC-1295 should be studied thoroughly before designing any protocol — study designs, dosing ranges, and outcome measures vary significantly and conclusions do not uniformly extrapolate.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
